Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 20 of 201

1.

Assessment of Tumor Sequencing as a Replacement for Lynch Syndrome Screening and Current Molecular Tests for Patients With Colorectal Cancer.

Hampel H, Pearlman R, Beightol M, Zhao W, Jones D, Frankel WL, Goodfellow PJ, Yilmaz A, Miller K, Bacher J, Jacobson A, Paskett E, Shields PG, Goldberg RM, de la Chapelle A, Shirts BH, Pritchard CC; Ohio Colorectal Cancer Prevention Initiative Study Group.

JAMA Oncol. 2018 Mar 29. doi: 10.1001/jamaoncol.2018.0104. [Epub ahead of print]

PMID:
29596542
2.

STAT3/PIAS3 Levels Serve as "Early Signature" Genes in the Development of High-Grade Serous Carcinoma from the Fallopian Tube.

Saini U, Suarez AA, Naidu S, Wallbillich JJ, Bixel K, Wanner RA, Bice J, Kladney RD, Lester J, Karlan BY, Goodfellow PJ, Cohn DE, Selvendiran K.

Cancer Res. 2018 Apr 1;78(7):1739-1750. doi: 10.1158/0008-5472.CAN-17-1671. Epub 2018 Jan 16.

PMID:
29339537
3.

MAX Mutations in Endometrial Cancer: Clinicopathologic Associations and Recurrent MAX p.His28Arg Functional Characterization.

Walker CJ, Rush CM, Dama P, O'Hern MJ, Cosgrove CM, Gillespie JL, Zingarelli RA, Smith B, Stein ME, Mutch DG, Shakya R, Chang CW, Selvendiran K, Song JW, Cohn DE, Goodfellow PJ.

J Natl Cancer Inst. 2018 May 1;110(5):517-526. doi: 10.1093/jnci/djx238.

PMID:
29155953
4.

Moving forward with actionable therapeutic targets and opportunities in endometrial cancer: NCI clinical trials planning meeting report on identifying key genes and molecular pathways for targeted endometrial cancer trials.

MacKay HJ, Levine DA, Bae-Jump VL, Bell DW, McAlpine JN, Santin A, Fleming GF, Mutch DG, Nephew KP, Wentzensen N, Goodfellow PJ, Dorigo O, Nijman HW, Broaddus R, Kohn EC.

Oncotarget. 2017 Aug 3;8(48):84579-84594. doi: 10.18632/oncotarget.19961. eCollection 2017 Oct 13. Review.

5.

An NRG Oncology/GOG study of molecular classification for risk prediction in endometrioid endometrial cancer.

Cosgrove CM, Tritchler DL, Cohn DE, Mutch DG, Rush CM, Lankes HA, Creasman WT, Miller DS, Ramirez NC, Geller MA, Powell MA, Backes FJ, Landrum LM, Timmers C, Suarez AA, Zaino RJ, Pearl ML, DiSilvestro PA, Lele SB, Goodfellow PJ.

Gynecol Oncol. 2018 Jan;148(1):174-180. doi: 10.1016/j.ygyno.2017.10.037. Epub 2017 Nov 11.

6.

Novel SOX17 frameshift mutations in endometrial cancer are functionally distinct from recurrent missense mutations.

Walker CJ, O'Hern MJ, Serna VA, Kurita T, Miranda MA, Sapp CE, Mutch DG, Cohn DE, Goodfellow PJ.

Oncotarget. 2017 Aug 12;8(40):68758-68768. doi: 10.18632/oncotarget.20213. eCollection 2017 Sep 15.

7.

Primum non nocere: Are we ready for POLE testing in endometrial cancer?

Cosgrove CM, Cohn DE, Goodfellow PJ.

Gynecol Oncol. 2017 Nov;147(2):240-242. doi: 10.1016/j.ygyno.2017.09.015. Epub 2017 Sep 22. No abstract available.

8.

The FOXA2 transcription factor is frequently somatically mutated in uterine carcinosarcomas and carcinomas.

Le Gallo M, Rudd ML, Urick ME, Hansen NF; National Institutes of Health Intramural Sequencing Center Comparative Sequencing Program, Merino MJ, Mutch DG, Goodfellow PJ, Mullikin JC, Bell DW.

Cancer. 2018 Jan 1;124(1):65-73. doi: 10.1002/cncr.30971. Epub 2017 Sep 21.

PMID:
28940304
9.

Epigenetic silencing of MLH1 in endometrial cancers is associated with larger tumor volume, increased rate of lymph node positivity and reduced recurrence-free survival.

Cosgrove CM, Cohn DE, Hampel H, Frankel WL, Jones D, McElroy JP, Suarez AA, Zhao W, Chen W, Salani R, Copeland LJ, O'Malley DM, Fowler JM, Yilmaz A, Chassen AS, Pearlman R, Goodfellow PJ, Backes FJ.

Gynecol Oncol. 2017 Sep;146(3):588-595. doi: 10.1016/j.ygyno.2017.07.003. Epub 2017 Jul 11.

10.

Somatic mutation profiles of clear cell endometrial tumors revealed by whole exome and targeted gene sequencing.

Le Gallo M, Rudd ML, Urick ME, Hansen NF, Zhang S; NISC Comparative Sequencing Program, Lozy F, Sgroi DC, Vidal Bel A, Matias-Guiu X, Broaddus RR, Lu KH, Levine DA, Mutch DG, Goodfellow PJ, Salvesen HB, Mullikin JC, Bell DW.

Cancer. 2017 Sep 1;123(17):3261-3268. doi: 10.1002/cncr.30745. Epub 2017 May 9.

PMID:
28485815
11.

Integrative analysis identifies targetable CREB1/FoxA1 transcriptional co-regulation as a predictor of prostate cancer recurrence.

Sunkel B, Wu D, Chen Z, Wang CM, Liu X, Ye Z, Horning AM, Liu J, Mahalingam D, Lopez-Nicora H, Lin CL, Goodfellow PJ, Clinton SK, Jin VX, Chen CL, Huang TH, Wang Q.

Nucleic Acids Res. 2017 Jun 20;45(11):6993. doi: 10.1093/nar/gkx282. No abstract available.

12.

FGFR2 mutations are associated with poor outcomes in endometrioid endometrial cancer: An NRG Oncology/Gynecologic Oncology Group study.

Jeske YW, Ali S, Byron SA, Gao F, Mannel RS, Ghebre RG, DiSilvestro PA, Lele SB, Pearl ML, Schmidt AP, Lankes HA, Ramirez NC, Rasty G, Powell M, Goodfellow PJ, Pollock PM.

Gynecol Oncol. 2017 May;145(2):366-373. doi: 10.1016/j.ygyno.2017.02.031. Epub 2017 Mar 15.

13.

Identification of endometrial cancer methylation features using combined methylation analysis methods.

Trimarchi MP, Yan P, Groden J, Bundschuh R, Goodfellow PJ.

PLoS One. 2017 Mar 9;12(3):e0173242. doi: 10.1371/journal.pone.0173242. eCollection 2017.

14.

Prevalence and Spectrum of Germline Cancer Susceptibility Gene Mutations Among Patients With Early-Onset Colorectal Cancer.

Pearlman R, Frankel WL, Swanson B, Zhao W, Yilmaz A, Miller K, Bacher J, Bigley C, Nelsen L, Goodfellow PJ, Goldberg RM, Paskett E, Shields PG, Freudenheim JL, Stanich PP, Lattimer I, Arnold M, Liyanarachchi S, Kalady M, Heald B, Greenwood C, Paquette I, Prues M, Draper DJ, Lindeman C, Kuebler JP, Reynolds K, Brell JM, Shaper AA, Mahesh S, Buie N, Weeman K, Shine K, Haut M, Edwards J, Bastola S, Wickham K, Khanduja KS, Zacks R, Pritchard CC, Shirts BH, Jacobson A, Allen B, de la Chapelle A, Hampel H; Ohio Colorectal Cancer Prevention Initiative Study Group.

JAMA Oncol. 2017 Apr 1;3(4):464-471. doi: 10.1001/jamaoncol.2016.5194.

15.

Traditional Approaches to Molecular Genetic Analysis.

Walker CJ, Goodfellow PJ.

Adv Exp Med Biol. 2017;943:99-118. Review.

PMID:
27910066
16.

The mutational spectrum of FOXA2 in endometrioid endometrial cancer points to a tumor suppressor role.

Smith B, Neff R, Cohn DE, Backes FJ, Suarez AA, Mutch DG, Rush CM, Walker CJ, Goodfellow PJ.

Gynecol Oncol. 2016 Nov;143(2):398-405. doi: 10.1016/j.ygyno.2016.08.237. Epub 2016 Aug 15.

17.

MonoSeq Variant Caller Reveals Novel Mononucleotide Run Indel Mutations in Tumors with Defective DNA Mismatch Repair.

Walker CJ, Miranda MA, O'Hern MJ, Blachly JS, Moyer CL, Ivanovich J, Kroll KW, Eisfeld AK, Sapp CE, Mutch DG, Cohn DE, Bundschuh R, Goodfellow PJ.

Hum Mutat. 2016 Oct;37(10):1004-12. doi: 10.1002/humu.23036. Epub 2016 Aug 8.

18.

Clinicopathologic Significance of Mismatch Repair Defects in Endometrial Cancer: An NRG Oncology/Gynecologic Oncology Group Study.

McMeekin DS, Tritchler DL, Cohn DE, Mutch DG, Lankes HA, Geller MA, Powell MA, Backes FJ, Landrum LM, Zaino R, Broaddus RD, Ramirez N, Gao F, Ali S, Darcy KM, Pearl ML, DiSilvestro PA, Lele SB, Goodfellow PJ.

J Clin Oncol. 2016 Sep 1;34(25):3062-8. doi: 10.1200/JCO.2016.67.8722. Epub 2016 Jun 20.

19.

Frequent PIK3CA Mutations in Colorectal and Endometrial Tumors With 2 or More Somatic Mutations in Mismatch Repair Genes.

Cohen SA, Turner EH, Beightol MB, Jacobson A, Gooley TA, Salipante SJ, Haraldsdottir S, Smith C, Scroggins S, Tait JF, Grady WM, Lin EH, Cohn DE, Goodfellow PJ, Arnold MW, de la Chapelle A, Pearlman R, Hampel H, Pritchard CC.

Gastroenterology. 2016 Sep;151(3):440-447.e1. doi: 10.1053/j.gastro.2016.06.004. Epub 2016 Jun 11.

20.

Elevated STAT3 expression in ovarian cancer ascites promotes invasion and metastasis: a potential therapeutic target.

Saini U, Naidu S, ElNaggar AC, Bid HK, Wallbillich JJ, Bixel K, Bolyard C, Suarez AA, Kaur B, Kuppusamy P, Hays J, Goodfellow PJ, Cohn DE, Selvendiran K.

Oncogene. 2017 Jan 12;36(2):168-181. doi: 10.1038/onc.2016.197. Epub 2016 Jun 13.

Supplemental Content

Loading ...
Support Center